
    
      This is a phase three multicentre, double blind, randomize parallel group, placebo-controlled
      study in 250 men with histologically proven cancer without bone metastases who are beginning
      ADT therapy and who will receive a concomitant treatment with either oral Fosamax 70 mg once
      a weak (n=125) or placebo (n=125) for one year. Changes in BMD, markers of bone absorption
      and formation are monitored.
    
  